Global colorectal cancer screening market is estimated to be valued at USD 15.44 Bn in 2024, and is expected to exhibit a CAGR of 7.1% during the forecast period (2024-2031). Colorectal cancer (CRC) is one of the most commonly diagnosed cancers globally. It arises from the transformation of normal epithelial cell lining in the colon or rectum into cancerous tumors. Several factors such as age, diet, lifestyle and genetic conditions can increase the risk of developing CRC. Screening tests help in early detection of cancer, especially in high risk individuals. Global initiatives to spread awareness and availability of improved screening technologies are expected to drive the colorectal cancer screening market growth.

Market Dynamics:

Rising awareness initiatives by governments and cancer organizations is expected to drive the colorectal cancer screening market growth globally. For example, programs such as the National Colorectal Cancer Awareness Month in the U.S. promotes the importance of screening tests via social media campaigns. However, limited access to screening tests in remote areas and social stigma associated with the tests can hamper the market growth. Development of non-invasive diagnostic approaches such as blood-based biomarker tests offers lucrative opportunities for the market growth.

Key Features of the Study:

• This report provides an in-depth analysis of the global colorectal cancer screening market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global colorectal cancer screening market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers AG, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, Clinical Genomics Technologies Pty Ltd., Clinical Genomics, Guardant Health, Inc., Hemosure Inc., Geneoscopy, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global colorectal cancer screening market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global colorectal cancer screening market.

Detailed Segmentation-

• By Screening Tests:
  • Stool-based Tests
  • Colonoscopy
  • CT Colonography 
  • Flexible Sigmoidoscopy
  • Others
• By End User:
  • Hospitals
  • Specialty Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Polymedco Inc.
  • Eiken Chemical Co. Ltd.
  • Sysmex Corporation
  • Siemens Healthineers AG
  • Quidel Corporation
  • Novigenix SA
  • Hemosure Inc.
  • Exact Sciences Corp.
  • Epigenomics Inc.
  • Olympus Corporation
  • Clinical Genomics Technologies Pty Ltd.
  • Clinical Genomics
  • Guardant Health, Inc.
  • Hemosure Inc.
  • Geneoscopy, Inc.